Skip to Main Content
Contribute Try STAT+ Today

As the White House gets set to name a new head of the U.S. Patent & Trademark Office, a coalition of advocacy and nonprofit groups see an opportunity to overhaul the approach to issuing patents that may sometimes prevent Americans from accessing needed medicines.

For the past several years, patent protection has become a flashpoint in the wider debate over the rising cost of prescription medicines in the U.S. The issue reflects concerns that drug makers have increasingly been granted patents that arguably add little to medical innovation, but extend monopolies that not only forestall lower-cost competition but also permit ongoing price hikes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment